AI Article Synopsis
- Researchers are focusing on creating drugs that target epigenetic changes, particularly enzymes involved in histone acetylation and DNA methylation.
- Changes in these processes are linked to cancer and leukemia, making them promising targets for treatment.
- Early clinical trials for drugs that modify DNA methylation and histone acetylation are showing positive outcomes, and there is potential for these drugs to be beneficial in other areas of medicine as well.
Article Abstract
Therapeutic approaches aimed at developing epigenetically-effective drugs are under intense investigation. Several classes of enzymes regulating histone acetylation and DNA methylation, which are required for epigenetic transitions, offer attractive targets for therapeutic interventions. Imbalances in histone acetylation and DNA methylation may play a significant role in the development of cancer and leukaemia and may provide a mechanistic rationale for targeting epigenetic modifications. Clinical trials designed to evaluate inhibitors of DNA methylation and histone deacetylase inhibitors are showing encouraging results in cancer patients. A growing quantity of data from preclinical research supports the notion that epigenetically-effective drugs could also find an application in other therapeutic areas. A number of emerging biomarkers may prove useful for monitoring drug effects and defining molecular signatures of response, toxicity and effective dose.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/14728222.7.6.693 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!